Publication |
2010
Abstract
Trimetazidine is a selective inhibitor of 3-ketoacyl-coenzyme A-thiolase. After its administration during hypoxia β-oxidation of free fatty acid is blocked with metabolic switch in favour of glucose oxidation.
During glucose oxidation less oxygen is consumed for production of one molecule of adenosine triphosphate. As a result, the cell acidosis and its consequences are attenuated.
Studies with trimetazidine during revascularization procedures, which support the favourable effect of trimetazidine on severity of ischemia, myocardial necrosis and ischemic-reperfusion injury, are reviewed in this article